Skip to main content
Acute Respiratory IllnessDiagnostics and screeningChildren's healthHealthy volunteersDevice

What this study is

Simplified from ClinicalTrials.gov

Testing a breath analyzer (MBP® Breath Analyzer) to see if it can collect measurable chemical signals from the breath of children ages 7 to 17 with signs or symptoms of sudden respiratory illness who come to the Masonic Children's Hospital pediatric emergency department. Healthy children there for minor injuries take part as comparisons.

Read the original summary from ClinicalTrials.gov

This pilot study will evaluate whether the MBP® Breath Analyzer can collect measurable volatile organic compound signals from pediatric participants with acute respiratory illness and from healthy pediatric controls.

Children aged 7 to 17 years presenting to the Masonic Children's Hospital Pediatric Emergency Department will be enrolled. One group will include participants with signs or symptoms of acute respiratory illness, and the control group will include participants presenting for minor injuries without respiratory symptoms.

Participants will breathe normally into the MBP® Breath Analyzer for approximately 1 minute. VOC signal data will be analyzed to assess device performance and to explore whether breath VOC patterns differ between pediatric participants with respiratory infection and healthy controls.

What's being tested

  • MBP® Breath Analyzer

    Intervention · DEVICE

    The MBP® Breath Analyzer is a handheld breath sensor connected to a secure dedicated study mobile phone with the Vocxi app. A mask is connected to the device, and the participant breathes normally into the mask for approximately 1 minute. The system collects volatile organic compound signal data from exhaled breath for research analysis. The device will not be used to diagnose, treat, or guide clinical care.

Study details

Official title
Vocxi Breath Analyzer Study
Sponsor
University of Minnesota
Conditions
Acute Respiratory Illness · Viral Respiratory Infection
Enrolling
20 people
Starts
2026-10-27
Est. completion
2027-03-01
Design
Open-label, non-randomized, parallel groups
Record
View on ClinicalTrials.gov ↗